CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

This study tests CD19-targeted CAR-T cell therapy — an engineered immune cell therapy — for patients with large B-cell lymphoma (an aggressive blood cancer) that has returned or stopped responding after at least two prior treatment lines, including stem cell transplant. **You may be eligible if...** - You are 18 or older - You have confirmed large B-cell lymphoma that has relapsed or failed at least two prior therapies (including anthracycline-based chemotherapy with rituximab and a stem cell transplant) - You have measurable disease on PET and CT scans - Your performance status is good (ECOG 0–1) with adequate organ function **You may NOT be eligible if...** - You have less than 3 months expected survival - You have had prior CAR-T therapy and your cancer no longer expresses CD19 - You have active uncontrolled infection or severe organ impairment Talk to your doctor to see if this trial is right for you.